Article
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Anticancer research - 1 Jan 2011
Wong Nan Soon, Fernando Nishan H, Nixon Andrew B, Cushman Stephanie, Aklilu Mebea, Bendell Johanna C, Morse Michael A, Blobe Gerard C, Ashton Jill, Pang Herbert, Hurwitz Herbert I
Abstract excerpt
AIM: This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer. PATIENTS AND METHODS: Patients with previously untreated advanced colorectal cancer received oxaliplatin 130 mg/m² and bevacizumab 7.5 mg/kg every three weeks, capecitabine 850 mg/m² twice daily on days 1-14, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.